These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 8783663)

  • 21. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
    Shipp NG; Dorr RT; Alberts DS; Dawson BV; Hendrix M
    Cancer Res; 1993 Feb; 53(3):550-6. PubMed ID: 8425187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of iron in doxorubicin-induced cardiomyopathy.
    Myers C
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):10-4. PubMed ID: 9768818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK; Schellens JH; Beijnen JH; Huitema AD
    Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
    J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel antioxidants in anthracycline cardiotoxicity.
    Hideg K; Kálai T
    Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.
    Khan M; Shobha JC; Mohan IK; Naidu MU; Sundaram C; Singh S; Kuppusamy P; Kutala VK
    Phytother Res; 2005 Dec; 19(12):1030-7. PubMed ID: 16372368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
    Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
    Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
    Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Herman EH; Zhang J; Chadwick DP; Ferrans VJ
    Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.